Phase II study of low dose suramin as a sensitizer of paclitaxel/carboplatin (P/C) in non small cell lung cancer (NSCLC)Miguel A. Villalona‐Calero, Jessie L.‐S. Au, G. Wientjes et al.|Journal of Clinical Oncology|2004Cited by 1